Offering images of high spatial resolution and a small system footprint, the new positron emission tomography (PET) modality from Radialis may facilitate enhanced imaging of emerging radiotracer agents and key biomarkers in targeted organs.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Radialis PET Imager, an emerging portable complement to traditional positron emission tomography/computed tomography (PET/CT) systems.
Specially designed for organ-targeted, close-range imaging, the Radialis PET Imager reportedly has increased sensitivity to radiotracer imaging agents, according to Radialis, the manufacturer of the device.
The company said the device combines a partial-ring plantar PET camera and lutetium-containing gamma ray detectors. The Radialis PET Imager can visualize any injected positron-emitting radiotracer agent and provide images of high spatial resolution, noted Radialis.
Radialis said the device also has two plantar detectors that can be adjusted as necessary to allow a variety of scans and adaptability to patients who are lying down, standing, or sitting. The portability of the 4.5 feet high device also facilitates smoother incorporation into existing nuclear medicine facilities, according to Radialis.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.